Pyxis Oncology
PYXS
39 hedge funds and large institutions have $47.7M invested in Pyxis Oncology in 2022 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 8 increasing their positions, 15 reducing their positions, and 16 closing their positions.
3.21% more ownership
Funds ownership: 57.83% → 61.04% (+3.2%)
13% less funds holding
Funds holding: 45 → 39 (-6)
31% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 16
37% less capital invested
Capital invested by funds: $76.1M → $47.7M (-$28.4M)
47% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 15
Top Buyers
| 1 |
LCM
Laurion Capital Management
New York
|
+$5.19M |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
+$3.67M |
| 3 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$2.57M |
| 4 |
NM
Newtyn Management
New York
|
+$2.13M |
| 5 |
ACP
Acuta Capital Partners
Redwood City,
California
|
+$1.19M |
Top Sellers
| 1 |
Janus Henderson Group
London,
United Kingdom
|
-$5.49M |
| 2 |
RI
RTW Investments
New York
|
-$3.83M |
| 3 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$3.54M |
| 4 |
HM
HealthCor Management
New York
|
-$879K |
| 5 |
BlackRock
New York
|
-$840K |
PYXS Hedge Fund Activity: Q2 2022 in Review
39 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Pyxis Oncology (PYXS) for Q2 2022, worth a combined $47.7M — down 37% from $76.1M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of PYXS and 11 opened new positions — a net loss of 5 holders — while 15 trimmed existing stakes and 8 added.
The largest buyer was Laurion Capital Management, adding an estimated $5.19M. The largest seller was Janus Henderson Group, exiting entirely with an estimated $5.49M sold.
- 39 institutional investors held Pyxis Oncology (PYXS) as of Q2 2022, down from 45 in Q1 2022.
- Funds reported $47.7M of Pyxis Oncology stock for Q2 2022, down 37% quarter-over-quarter.
- 11 funds opened new Pyxis Oncology positions in Q2 2022 and 16 closed out, a net change of -5 holders.
- The largest Pyxis Oncology buyer in Q2 2022 was Laurion Capital Management, an estimated $5.19M added.
- The largest Pyxis Oncology seller in Q2 2022 was Janus Henderson Group, an estimated $5.49M sold.
Based on aggregated 13F filings for Q2 2022.